echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lung cancer is overweight! Opdivo plus chemotherapy preoperative therapy can remove NSCLC Phase 3 clinical: significantly improve pathology complete remission rate (pCR)!

    Lung cancer is overweight! Opdivo plus chemotherapy preoperative therapy can remove NSCLC Phase 3 clinical: significantly improve pathology complete remission rate (pCR)!

    • Last Update: 2020-10-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    October 08, 2020 // -- BMS recently announced the evaluation of the anti-PD-1 therapy Opdivo (Odivo, generic name: nivolumab, Navuliyu single resistance) The Phase 3 CheckMate-816 trial for excisive non-small cell lung cancer (NSCLC) patients with new complementary therapy (preoperative therapy) reached its main endpoint: a significant statistical improvement in pathological complete remission (pCR).
    it is worth noting that CheckMate-816 was the first and only Phase 3 trial: it was shown that immuno-checkpoint inhibitor combination chemotherapy was beneficial as a new complementary treatment for non-metastasis NSCLC.
    CheckMate-816 is a randomized, open-label, multi-center Phase 3 trial that is evaluating the efficacy of Opdivo combined chemotherapy and single-use chemotherapy as a new complementary treatment for patients with removable NSCLC.
    In the main analysis, 358 patients were randomly divided into two groups, one group receiving Opdivo 360mg combined with histological platinum-based double chemotherapy (platinum-doublet chemotherapy, PDC), once every three weeks, up to three times, followed by surgery, and the other group receiving PDC, once every three weeks, up to three times, and then surgery.
    the main endpoints of the trial were pathological complete remission (pCR) and event-free lifetime (EFS).
    secondary endpoints include total lifetime (OS), primary pathological remission (MPR), death, or distant transfer time.
    results showed that the study reached the main endpoint of pCR: a higher proportion of patients who received Opdivo plus chemotherapy as a new complementary treatment before surgery showed no signs of cancer cells in surgically removed tissue than in the group receiving chemotherapy as a new auxiliary treatment.
    the study, the safety of Opdivo combined chemotherapy was consistent with previously reported NSCLC studies.
    positive results mark the first time in a phase 3 trial of removable NSCLC that a combination therapy based on immunosuppressants is more effective as a new complementary treatment than chemotherapy.
    so far, Opdivo-based programs have shown benefits in four Phase 3 clinical trials for early-stage cancer, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer, and melanoma.
    BMS will complete a comprehensive assessment of existing CheckMate-816 data and work with investigators to present the results at an upcoming medical conference while discussing potential regulatory options with regulators.
    CheckMate-816 trial is currently under way to assess the main endpoint of event-free lifetime (EFS) and the critical secondary endpoint.
    in non-metastasis NSCLC, BMS and its partners are exploring the application of immunotherapy in the new assisted, assisted and peri-surgical period, as well as in combination with chemotherapy.
    to date, Opdivo has shown better results in new complementary or complementary treatments for four types of cancer: lung, bladder, esophageal/gastroesophageal cancer and melanoma.
    is the leading cause of cancer death worldwide.
    types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
    NSCLC is one of the most common types of lung cancer, accounting for 84% of lung cancer cases.
    non-transferable cases account for the majority (approximately 60%) of NSCLC cases.
    Although many patients with non-metastasis NSCLC are cured surgically, 30%-55% of non-metastasis NSCLC recurrences and deaths require preoperative (new assisted) and/or postoperative (assisted) treatment options to improve long-term prognostication.
    as many as half of patients with non-metastasis lung cancer undergoing surgery will have a recurrence of the disease," said Mark Awad, M.D., clinical director of the Lowe Chest Cancer Center at the Dana Farber Cancer Institute.
    Opdivo has shown an advantage as an ancillary treatment (postoperative treatment) in other cancer types, and the positive results of CheckMate-816 demonstrate Opdivo's potential in a new complementary treatment (preoperative therapy) for small cell lung cancer.
    Opdivo combined chemotherapy as a new complementary therapy for the treatment of small cell lung cancer, improvements in pathological total remission have the potential to lead to longer event-free survival and ultimately improve overall survival.
    "The results of CheckMate-816 build on the tradition of BMS treating chest cancer, and Opdivo-based programs have been shown to have a higher total survival in patients treating metastasis non-small cell lung cancer and non-removable malignant pletrial mesothelioma," said Abderrahim Oukesou, vice president and director of chest cancer development at BMS.
    addition, these data increase our understanding of the potential of immunotherapy to transform outcomes in different early stages of cancer, at which stage the immune system may be more responsive.
    we thank the patients and investigators involved in the CheckMate-816 trial.
    ": Opdivo (nivolumab) Plus Processy Display Statistically Significant Improve in Pathologic Complete Response as Neoadjuvant Treatment of Resectable Non-Small Cell Cell Cancer in Phase 3 CheckMate -816 Trial.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.